Rekvina Laboratories Ltd
BSE: VINRKLB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Rekvina Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Rekvina Labs Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of diverse dosage forms, including tablets, capsules, and liquid orals. The firm operates as both a contract manufacturer and a supplier of generic medicines across various therapeutic segments.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations, serving both domestic and international markets. It leverages its manufacturing facilities to provide contract manufacturing services alongside its own generic medicine supply chain.
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its generic medicine portfolio and leveraging its contract manufacturing capabilities. The firm aims to maintain its regional presence by adhering to quality standards and regulatory compliance.
Key Risks
- Regulatory Compliance. Failure to maintain stringent manufacturing standards could lead to regulatory sanctions or loss of product approvals.
- Market Competition. The company faces intense competition from larger pharmaceutical players, which may exert pressure on pricing and profit margins.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact operational profitability.
- Export Dependency. Exposure to international markets introduces risks related to geopolitical instability and varying regulatory requirements across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Rekvina Laboratories Ltd and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Rekvina Laboratories LtdVINRKLB | ₹29 Cr | — | — | — | -19.7% | — | — | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Rekvina Laboratories Ltd
BSE: VINRKLB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Rekvina Laboratories Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Rekvina Labs Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of diverse dosage forms, including tablets, capsules, and liquid orals. The firm operates as both a contract manufacturer and a supplier of generic medicines across various therapeutic segments.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations, serving both domestic and international markets. It leverages its manufacturing facilities to provide contract manufacturing services alongside its own generic medicine supply chain.
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its generic medicine portfolio and leveraging its contract manufacturing capabilities. The firm aims to maintain its regional presence by adhering to quality standards and regulatory compliance.
Key Risks
- Regulatory Compliance. Failure to maintain stringent manufacturing standards could lead to regulatory sanctions or loss of product approvals.
- Market Competition. The company faces intense competition from larger pharmaceutical players, which may exert pressure on pricing and profit margins.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact operational profitability.
- Export Dependency. Exposure to international markets introduces risks related to geopolitical instability and varying regulatory requirements across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Rekvina Laboratories Ltd and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026